echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Chengdu Beite won the first imitation of 20 new products of "Hepatitis B Magic Medicine" on the road

    Chengdu Beite won the first imitation of 20 new products of "Hepatitis B Magic Medicine" on the road

    • Last Update: 2020-10-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medicine Network October 21 - Fumarate propofol novovir (TAF) is a strong antiviral drug for the treatment of chronic hepatitis B in adults and adolescents, with fumarate novovir dipropide (TDF), Entikavir (ETV) is the same nucleoside (acid) drugs, and listed in the global hepatitis B treatment guidelines three first-line drugs.
    ,000-based propofol-nofovir tablet, developed by Gilead and called Vemlidy, is known as "the strongest hepatitis B drug in history."
    2019, Vemlidy's global sales were $488 million, up 52.02 percent year-on-year.
    's Vemlidy was approved to enter the domestic market in November 2018.
    meters of intranet data show that in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal propofol for Nofowe sales of more than 30 million yuan.
    fumarate propofol for the new classification of production of Novowe tablets Mienet data show that there are currently 16 pharmaceutical companies to copy 3 or imitation 4 categories to submit a fumarate propofol to nofowe tablets market application.
    , Chengdu Bett Pharmaceuticals took the lead in September 23 into the administrative approval stage, October 19 successfully became the first imitation in China.
    to date, Chengdu Bett Pharmaceuticals has 20 varieties (29 acceptance numbers) of generic drugs reported in the new classification reviewed and will be treated as if they had passed a consistency evaluation after being approved for production.
    7 out of 20 varieties of new classified generics reviewed by Chengdu Pharmaceuticals have not been approved for sale in the domestic market, including Shakuba quercetin sodium tablets, hydrobrominate vositin tablets, and estalfeline phosphate Mixed suspension agent, methyl sulfonate lunvatini capsules, entourtabin propofol nofowei tablets, hydrochloric acid right metominated sodium chloride injection, cephalosporine particles, etc. , Chengdu Vit Pharmaceuticals will compete with a number of pharmaceutical companies for the first imitation.
    source: MiNet database, State Drug Administration.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.